B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 2.6 ILS
Market Cap: 59.6m ILS

Relative Value

The Relative Value of one BLRX stock under the Base Case scenario is 16.89 ILS. Compared to the current market price of 2.6 ILS, BioLine RX Ltd is Undervalued by 85%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BLRX Relative Value
Base Case
16.89 ILS
Undervaluation 85%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
85
Median 3Y
0
Median 5Y
0
Industry
7.1
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-5.8
Industry
22.9
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-8.4
Industry
19.4
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-7.9
Industry
22.6
vs History
93
vs Industry
60
Median 3Y
4.1
Median 5Y
6.6
Industry
2.7
vs History
vs Industry
67
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
59
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
4
vs Industry
28
Median 3Y
-2.9
Median 5Y
-6.2
Industry
4.5
vs History
4
vs Industry
27
Median 3Y
-2.8
Median 5Y
-6.1
Industry
4.5
vs History
4
vs Industry
29
Median 3Y
-3.3
Median 5Y
-7
Industry
5
vs History
4
vs Industry
24
Median 3Y
-3.3
Median 5Y
-6.9
Industry
3.7
vs History
vs Industry
46
Median 3Y
5.9
Median 5Y
12.3
Industry
4.9

Multiples Across Competitors

BLRX Competitors Multiples
BioLine RX Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
BioLine RX Ltd
TASE:BLRX
59.6m ILS 0.8 -5.2 0 0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 829 747 -160 787.8 -195 247.6 -193 019.6
US
Abbvie Inc
NYSE:ABBV
322B USD 5.6 77.5 14.8 21.9
US
Amgen Inc
NASDAQ:AMGN
149B USD 4.4 25.1 13.7 22.6
US
Gilead Sciences Inc
NASDAQ:GILD
137.8B USD 4.8 23.1 10 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD 10.2 -114.7 24.3 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 082.5 -531.4 -578.6 -563.2
AU
CSL Ltd
ASX:CSL
116B AUD 5 27.6 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.4B USD 4 12.5 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.1B USD 17.9 -156 -699.8 -350.7
P/E Multiple
Earnings Growth PEG
IL
B
BioLine RX Ltd
TASE:BLRX
Average P/E: 33.2
Negative Multiple: -5.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 787.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
B
BioLine RX Ltd
TASE:BLRX
Average EV/EBITDA: 13
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 247.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
B
BioLine RX Ltd
TASE:BLRX
Average EV/EBIT: 16.8
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 019.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.7 N/A N/A